Volume 146, Issue 3, Pages 504-513 (September 2017) Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo, Andrea DeCensi Gynecologic Oncology Volume 146, Issue 3, Pages 504-513 (September 2017) DOI: 10.1016/j.ygyno.2017.06.036 Copyright © 2017 The Authors Terms and Conditions
Fig. 1 Flow diagram of study search and selection. Gynecologic Oncology 2017 146, 504-513DOI: (10.1016/j.ygyno.2017.06.036) Copyright © 2017 The Authors Terms and Conditions
Fig. 2 Forest plot of the association between endocrine therapy by type of drug and summary clinical benefit rate (SCBR) in ovarian cancer. Gynecologic Oncology 2017 146, 504-513DOI: (10.1016/j.ygyno.2017.06.036) Copyright © 2017 The Authors Terms and Conditions
Fig. 3 Forest plot of the association between endocrine therapy by hormone receptors status and summary clinical benefit rate (SCBR) in ovarian cancer. Gynecologic Oncology 2017 146, 504-513DOI: (10.1016/j.ygyno.2017.06.036) Copyright © 2017 The Authors Terms and Conditions
Fig. 4 Forest plot of the association between endocrine therapy by responsiveness to platinum-based chemotherapy and summary clinical benefit rate (SCBR) in ovarian cancer. Gynecologic Oncology 2017 146, 504-513DOI: (10.1016/j.ygyno.2017.06.036) Copyright © 2017 The Authors Terms and Conditions
Fig. 5 Forest plot of the association between endocrine therapy and summary estimate for death risk stratified by first line regimen. Gynecologic Oncology 2017 146, 504-513DOI: (10.1016/j.ygyno.2017.06.036) Copyright © 2017 The Authors Terms and Conditions
Fig. 6 Forest plot of the association between endocrine therapy and summary estimate for death risk stratified by tumor grade. Gynecologic Oncology 2017 146, 504-513DOI: (10.1016/j.ygyno.2017.06.036) Copyright © 2017 The Authors Terms and Conditions
Supplementary Fig. 1 Forest plot of the association between endocrine therapy by tamoxifen dose and summary clinical benefit (SCBR) in ovarian cancer. Gynecologic Oncology 2017 146, 504-513DOI: (10.1016/j.ygyno.2017.06.036) Copyright © 2017 The Authors Terms and Conditions